Filing Flows › Integrated Biopharma (INBP) › How it makes money
How Integrated Biopharma (INBP) makes money
Integrated Biopharma (INBP) made $9.8M of revenue in the fourth quarter fiscal 2026 (Q4 FY26). Contract Manufacturing brought in $9.5M (97%); Other Nutraceutical Business brought in $318K (3%).
Drawing the Sankey…
Revenue by segment, Q4 FY26
| Segment | Revenue | Share | Q/Q | Y/Y |
|---|---|---|---|---|
| Contract Manufacturing | $9.5M | 96.8% | -4% | — |
| Other Nutraceutical Business | $318K | 3.2% | +12% | — |
Where each dollar of revenue goes
| Line | Q4 FY26 | % of revenue |
|---|---|---|
| Revenue | $9.8M | 100.0% |
| Income tax | $516K | 5.3% |
Revenue, quarter by quarter
| Quarter | Revenue | Y/Y |
|---|---|---|
| Q4 FY26 | $9.8M | -31% |
| Q3 FY26 | $10.1M | -28% |
| Q2 FY26 | $11.3M | -11% |
| Q1 FY26 | $12.7M | -7% |
| Q4 FY25 | $14.2M | +11% |
| Q3 FY25 | $13.9M | +6% |
| Q2 FY25 | $12.6M | +10% |
From Integrated Biopharma's 10-K filed Sep 25, 2026 (on EDGAR).
Questions
How does Integrated Biopharma make money?
Integrated Biopharma (INBP) made $9.8M of revenue in the fourth quarter fiscal 2026 (Q4 FY26). Contract Manufacturing brought in $9.5M (97%); Other Nutraceutical Business brought in $318K (3%).
What is Integrated Biopharma's biggest business?
Contract Manufacturing: $9.5M in the fourth quarter fiscal 2026, 97% of revenue.
Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.